Taiwan-based Formosa Pharmaceuticals has entered into a collaboration agreement with US-based Eyenovia, Inc. for the development of novel ophthalmic therapeutics. The foundation of the collaboration lies in the combination of Formosa's APNT formulation platform with Eyenovia's Optejet delivery system. 

Eyenovia's Optejet delivery platform for ocular therapeutics utilises Microdose Array Print (MAP) technology to deliver 6-8 microliters of drug product, consistent with the capacity of the tear film of the eye. 

At less than 20% volume of that delivered by conventional eyedroppers, Optejet reduces the risk of overdosing and unnecessary drug exposure.  Furthermore, the Optejet action is both rapid and gentle, ensuring efficient and comfortable delivery to the ocular surface.

Formosa's proprietary APNT formulation platform improves dissolution and bioavailability of active pharmaceutical ingredients via a mild and efficient particle size reduction technique optimized for topical, oral, or inhaler administration routes.  Resulting formulations have high uniformity, purity, and stability, thereby allowing the utilisation of poorly soluble or extremely potent drug agents which otherwise may face insurmountable challenges in delivery and penetration to target tissues.

Erick Co, Chief Executive Officer of Formosa Pharmaceuticals said,  "Each company's proprietary technology enables the efficient use of existing and untapped agents in new indications.  Together, APNT and Optejet have obvious synergies and thus a high potential to unlock a wide new range of ophthalmic therapeutics and applications.  We are keen to launch this collaboration as quickly as possible."